Navigation Links
Schering-Plough Reports Financial Results for 2009 Second Quarter
Date:7/21/2009

wing that a greater proportion of anti-TNF-experienced patients with moderately to severely active rheumatoid arthritis who received subcutaneous injections of SIMPONI every four weeks experienced significant improvements in signs and symptoms compared with patients receiving placebo. (Announced June 10)
  • With Merck, reported the receipt of a request for additional information from the U.S. Federal Trade Commission with respect to the previously announced proposed merger. (Announced June 22)
  • Santarus, Inc. announced that Schering-Plough HealthCare Products, Inc. had received notification from the FDA of a December 2009 action date for an over-the-counter ZEGERID branded omeprazole/sodium bicarbonate product. (Announced June 23)
  • Schering-Plough and Merck scheduled special meetings of shareholders on Aug. 7, 2009, for purposes of voting on the proposed merger. The transaction is subject to shareholder approvals as well as the satisfaction of customary closing conditions and regulatory approvals, including expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, as well as clearance by the European Commission under the EC Merger Regulation and certain other foreign jurisdictions. (Announced June 25)
  • Reported results from the Phase III ENGAGE clinical trial demonstrating that a single injection of corifollitropin alfa, first in the class of sustained follicle stimulants, achieved similar efficacy to recombinant follicle stimulating hormone (rFSH) given once daily for seven days. (Announced July 1)
  • Extended to stage two an ongoing Phase II clinical study with vicriviroc, an investigational CCR5 antagonist, for use in first-line therapy of adult treatment-naive HIV-infected patients with R5-type virus only. (Announced July 15)
  • Merck and Schering-Plough and the companies' cholesterol joint venture, Merck/Sch
    '/>"/>

  • SOURCE Schering-Plough Corporation
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27

    Related biology technology :

    1. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
    2. Schering-Plough Announces Pricing of Senior Notes Offering
    3. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
    4. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
    5. Schering-Plough Completes Acquisition of Organon BioSciences
    6. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
    7. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
    8. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
    9. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
    10. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
    11. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/30/2014)... Nematicide is a type of chemical ... parasitic roundworms, found in massive quantities virtually everywhere—in ... animals. Nematicides have tended to be broad-spectrum toxicants ... through the soil. A single gram of soil ... more than 10,000 species classified, they are one ...
    (Date:9/30/2014)... 30, 2014 Follow us on ... each type of cholesterol carrier or lipoprotein in the ... excessive cholesterol levels in the body, especially along the ... heart attack and other cardiovascular disorders. Cardiovascular Diseases (CVD) ... for cholesterol levels on a regular basis, to assess ...
    (Date:9/30/2014)... Fast, semi-automatic creation of ... documents ChemAxon , a leader ... for life science research, launches ChemCurator, an application ... from documents. Markush structures are essential ... and understanding Markush structures is a difficult and ...
    (Date:9/30/2014)... Sept. 30, 2014  KemPharm, Inc., a clinical-stage ... development of proprietary new molecular entity (NME) prodrugs, ... Trademark Office (USPTO) issued U.S. Patent No. 8,816,083 ... Acid, Benzoic Acid Derivatives and Heteroaryl Carboxylic Acid ... Use Thereof." The patent, which extends ...
    Breaking Biology Technology:Nematicides Market by Types (Fumigants, Organophosphates, Carbamate and Bio-Nematicides), Applications (Agrochemicals, Industrial, and Others), and Geography (North America, Europe, Asia-Pacific & ROW) - Global Trends & Forecasts to 2019 2Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 2Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 3Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 4ChemAxon Introduces ChemCurator for Chemical Information Extraction and Markush Structure Creation 2KemPharm, Inc. Receives Patent from the USPTO for Novel Prodrug of Hydromorphone, KP511 2
    ... CLINTON, N.J. and JERUSALEM, July 6 Ikaria Holdings, ... Ikaria has entered into an agreement to obtain a ... treatment for preventing pathological cardiac remodeling following acute myocardial ... phase I/II clinical trial, is administered via the coronary ...
    ... /PRNewswire-FirstCall/ - avVaa World Health Care Products Inc. (Pink ... of nationally branded therapeutic, natural skin and health care ... an agreement with 3PL Worldwide, Inc., for all Order ... CEO explains that "3PL Worldwide offers true multichannel support ...
    ... July 6 /PRNewswire-FirstCall/ -- Verenium Corporation (Nasdaq: ... the $29.5 million of outstanding 8% Senior Convertible Notes due ... July 1, 2009 is effective as of 8:00 a.m. today. ... with holders of 87% of the Notes, which is above ...
    Cached Biology Technology:IKARIA(R) to In-License BioLineRx's BL-1040 2IKARIA(R) to In-License BioLineRx's BL-1040 3avVaa World Health Care Products, Inc. Signs Agreement with 3PL Worldwide, Inc., for Order Management & Fulfillment for avVaa's Product 2Verenium Completes Amendment to 8% Senior Convertible Notes 2Verenium Completes Amendment to 8% Senior Convertible Notes 3Verenium Completes Amendment to 8% Senior Convertible Notes 4
    (Date:9/30/2014)... professor and Howard Hughes Medical Institute investigator, and ... recipients in the 2014 round of grants from ... BRAIN (Brain Research through Advancing Innovative Neurotechnologies) Initiative ... September 30, provides more than $3 million in ... , The BRAIN Initiative, launched last year, is ...
    (Date:9/30/2014)... German . FRANKFURT. ... in the world. Because they grow underground, people use trained ... of truffles is not only of interest to gourmets. A ... the Goethe University Frankfurt have discovered that the smell of ... trapped inside truffle fruiting bodies. , White truffles from the ...
    (Date:9/30/2014)... hope: A new research report published in October 2014 ... explains how scientists developed a synthetic version of a ... in human and mouse eggs similar to the natural ... fertilization. , "We believe that the results of this ... of human fertilization by providing a precise answer to ...
    Breaking Biology News(10 mins):Salk scientists receive $3 million for BRAIN Initiative grant 2On the trail of the truffle flavor 2Synthetic sperm protein raises the chance for successful in vitro fertilization 2
    ... used topically in many skin creams and cosmetics because ... Now, new research just published in the Journal of ... and how it might actually benefit skin from the ... cocoa may actually help improve the appearance of women's ...
    ... is the only culprit in the steady increase in the ... challenged by a scientist speaking at the 22nd annual conference ... Prague, Czech Republic, Wednesday 21 June 2006. Professor ... that his research had shown that improved nutrition, both maternal ...
    ... (LANP) have unveiled the "nanoegg," the latest addition ... of the versatile nanoshell, nanoeggs are asymmetric specks ... harnessed for molecular imaging, medical diagnostics, chemical sensing ... July 18 issue of the Proceedings of the ...
    Cached Biology News:New study reveals components of cocoa may enhance the appearance of the skin 2Nutrition a major factor in rise in twin pregnancies 2Nutrition a major factor in rise in twin pregnancies 3Rice scientists unveil 'nanoegg' 2